Approvals/TGA/NOVOMIX 50 FlexPen 3mL 50% soluble insulin aspart (rys) and 50% insulin aspart (rys) crystallised with protamine 300U/3mL injection syringe

Approved

STANDARD

NOVOMIX 50 FlexPen 3mL 50% soluble insulin aspart (rys) and 50% insulin aspart (rys) crystallised with protamine 300U/3mL injection syringe

Novo Nordisk Pharmaceuticals Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: 3cd191af07d2bed2
Company: Novo Nordisk Pharmaceuticals Pty Ltd
Type: Standard

Approval Details

Approval Id: 3cd191af07d2bed2
Product Name: NOVOMIX 50 FlexPen 3mL 50% soluble insulin aspart (rys) and 50% insulin aspart (rys) crystallised with protamine 300U/3mL injection syringe
Artg Id: 122411
Artg Name: NOVOMIX 50 FLEXPEN 3mL 50% soluble insulin aspart (rys) and 50% insulin aspart (rys) crystallised with protamine 300U/3mL injection syringe
Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd
Company Detail Path: /organization/novo-nordisk-pharmaceuticals-pty-limited
Artg Date: 2007-05-10
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Product Information: https://medical-cdn.nocode.com/drug_tga/d43f4b371c6b2c7a7e943d9fe2762a71.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

3cd191af07d2bed2

Type

Standard

Back to TGA Approvals